Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company

Astellas Pharma Inc. Reports Revenue Growth in FY2023, Driven by Xtandi and Padcev Sales

Fineline Cube Apr 29, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the year ended...

Company Drug

iRegene’s Pioneering Cell Therapy NouvNeu001 Administered in Wuhan for Parkinson’s Disease

Fineline Cube Apr 29, 2024

Wuhan-based cell therapy developer iRegene has reached a clinical milestone with the administration of its...

Company Deals

Kexing Pharmaceutical Secures Global Rights for Qingfeng’s Generic Olaparib

Fineline Cube Apr 29, 2024

China’s Kexing Pharmaceutical (SHA: 688136) has secured a global commercialization licensing agreement with Qingfeng Pharmaceutical...

Company Drug

Chengdu Kanghong Pharmaceutical Gets US FDA Nod for Clinical Trial of KH658 for Wet AMD

Fineline Cube Apr 29, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a leading pharmaceutical company based in China,...

Company Drug

CARsgen Therapeutics Submits CAPA Report to US FDA Following Clinical Hold

Fineline Cube Apr 29, 2024

CARsgen Therapeutics Holdings Ltd (HKG: 2171), a specialist in chimeric antigen receptor (CAR)-T cell therapies...

Company Drug

Yantai Dongcheng Pharmaceutical Receives NMPA Approval for Advanced Solid Tumor Therapy

Fineline Cube Apr 29, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China,...

Company Drug

Keymed Biosciences’ Stapokibart Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Study

Fineline Cube Apr 29, 2024

China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that its IL-4Rα monoclonal antibody...

Company Deals

Sirnaomics Partners with Hualan Biological to Develop and Commercialize RSV mRNA Vaccine in China

Fineline Cube Apr 28, 2024

Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering...

Company Drug

Pfizer’s Gene Therapy Beqvez Wins FDA Nod for Moderate-to-Severe Hemophilia B

Fineline Cube Apr 28, 2024

The US Food and Drug Administration (FDA) has granted marketing authorization to Pfizer (NYSE: PFE)...

Company Drug

Bio-Thera Solutions’ BAT1806 Receives Positive CHMP Recommendation for EU Approval

Fineline Cube Apr 28, 2024

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that the Committee for Medicinal Products for...

Company Drug

HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe

Fineline Cube Apr 28, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...

Policy / Regulatory

China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement

Fineline Cube Apr 28, 2024

The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus,...

Company Drug

Novartis’s Iptacopan (Fabhalta) Receives Marketing Approval in China for PNH Treatment

Fineline Cube Apr 28, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received marketing approval from China for its iptacopan...

Company Medical Device

Mindray Bio-Medical Electronics Reports 15.04% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 28, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for 2023,...

Company

United Imaging Healthcare Reports 23.52% YOY Revenue Growth in 2023, Driven by Strong Product Launches and Partnerships

Fineline Cube Apr 28, 2024

Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has reported impressive financial results for the year...

Company Drug

AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial

Fineline Cube Apr 28, 2024

AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing...

Company Policy / Regulatory

Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations

Fineline Cube Apr 28, 2024

Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...

Company Deals

Neusoft Medical Systems Partners with West China Hospital to Boost Indigenous Medical Tech Innovation

Fineline Cube Apr 28, 2024

China-based Neusoft Medical Systems Co., Ltd has entered into a strategic partnership with West China...

Company Deals

AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China

Fineline Cube Apr 28, 2024

Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received...

Company

Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups

Fineline Cube Apr 28, 2024

Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...

Posts pagination

1 … 363 364 365 … 661

Recent updates

  • Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer
  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.